Contemporary Incidence and Survival of Lung Neuroendocrine Neoplasms

What are the contemporary incidence trends and survival outcomes for patients with lung neuroendocrine neoplasms (NENs)?In this cohort study of 4479 patients, the incidence of lung NENs increased 2.87-fold from 2000 to 2020, primarily due to typical neuroendocrine tumors (NETs) and stage I disease. Ten-year overall survival was 40%, varying by histology and stage; for typical NETs and stage I tumors, non–cancer-related mortality exceeded lung cancer death within 2 and 3 years, respectively.These findings highlight the evolving epidemiology of lung NENs and suggest that tailoring surveillance and treatment strategies based on tumor subtype and risk of competing mortality are crucial.

Corresponding Author: Julie Hallet, MD, MSc, Department of Surgery, University of Toronto, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada (julie.hallet@sunnybrook.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.